PDGFR

Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

Retrieved on: 
Monday, December 4, 2023

BOSTON and ATLANTA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced the U.S. Food and Drug Administration has granted a pre-New Drug Application (pre-NDA) meeting to be held in January 2024 to discuss the requirements for approval of IkT-001Pro and to review the data establishing doses of IkT-001Pro bioequivalent to 400 mg and 600 mg imatinib mesylate. The Company expects to provide an update following the meeting.

Key Points: 
  • The Company expects to provide an update following the meeting.
  • “We are pleased that the FDA has granted a pre-NDA meeting to discuss the parameters for approval of IkT-001Pro,” stated Dr. Milton Werner, President and Chief Executive Officer of Inhibikase Therapeutics.
  • Across all doses, there were only mild adverse events observed, including just two adverse events for IkT-001Pro at the highest dose comparison.
  • Pharmacokinetic profiles for imatinib delivered by IkT-001Pro and imatinib mesylate were similar at equivalent doses.

87.5% ORR | Abbisko presented two clinical updates of Pimicotinib at the 2023 CTOS Annual Meeting

Retrieved on: 
Tuesday, November 7, 2023

SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) announced that two major clinical updates of its CSF-1R inhibitor pimicotinib(ABSK021)were presented at the 2023 Connective Tissue Oncology Society Annual Meeting, which is held in Ireland from November 1 to 4, 2023.

Key Points: 
  • SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) announced that two major clinical updates of its CSF-1R inhibitor pimicotinib(ABSK021)were presented at the 2023 Connective Tissue Oncology Society Annual Meeting, which is held in Ireland from November 1 to 4, 2023.
  • The two clinical updates include reporting the design of the pivotal global multi-center phase III clinical trial and the further update of the phase Ib clinical trial of pimicotinib.
  • In 2023, the U.S. FDA conferred Breakthrough Therapy Designation and the European Medicines Agency granted Priority Medicine Designation upon Pimicotinib treatment of TGCT.
  • Here, we report the phase 1b safety and efficacy results of Pimicotinib in TGCT patients over a 1-year follow-up.

Elevar Therapeutics Presents AACR 2023 Poster Demonstrating Rivoceranib as Most Selective VEGFR-2 Inhibitor When Compared to Other TKIs With Known Activity Against VEGFR-2

Retrieved on: 
Tuesday, April 18, 2023

The results of the analysis were shared today in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando.

Key Points: 
  • The results of the analysis were shared today in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando.
  • For the biochemical analysis, the activity of rivoceranib and 10 U.S. Food and Drug Administration (FDA)-approved TKIs with known activity against VEGFR-2 were compared against a panel of 270 kinases.
  • Substantial differences in overall residual kinase activity were observed across the panel of 270 kinases among the 11 inhibitors.
  • Rivoceranib is the most selective inhibitor of VEGFR-2 kinase activity among the tested inhibitors.

AB Science today announced publication of results from its positive study of masitinib in severe asthma uncontrolled by oral corticosteroids in the peer-reviewed Journal of Asthma and Allergy

Retrieved on: 
Tuesday, June 7, 2022

Results from this phase 3 study showed that corticosteroid-dependent severe asthma patients treated with masitinib at 6.0 mg/kg/d had a lower risk of severe asthma exacerbations compared with those in a placebo-control group that did not receive masitinib.

Key Points: 
  • Results from this phase 3 study showed that corticosteroid-dependent severe asthma patients treated with masitinib at 6.0 mg/kg/d had a lower risk of severe asthma exacerbations compared with those in a placebo-control group that did not receive masitinib.
  • Phase 3 study (AB07105) evaluating oral masitinib at 6 mg/kg/d versus placebo in severe asthma uncontrolled by oral corticosteroids (OCS) met its primary endpoint.
  • Masitinib significantly decreased the rate of severe asthma exacerbations in patients with severe asthma uncontrolled by OCS.
  • 13 months)
    Masitinib has a unique positioning in severe asthma, in terms of administration (oral administration), mechanism of action, targeted population, and broader eosinophil level.

Cogent Biosciences Reports Recent Business Highlights and First Quarter 2022 Financial Results

Retrieved on: 
Tuesday, May 10, 2022

CAMBRIDGE, Mass. and BOULDER, Colo., May 10, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced financial results for the first quarter ended March 31, 2022.

Key Points: 
  • and BOULDER, Colo., May 10, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.(Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced financial results for the first quarter endedMarch 31, 2022.
  • We continue to make significant progress towards our strategic priorities for 2022, said Andrew Robbins, President and CEO of Cogent Biosciences.
  • R&D Expenses: Research and development expenses were $25.5 million for the first quarter of 2022 compared to $8.2 million for the first quarter of 2021.
  • G&A Expenses:General and administrative expenses were $5.9 million for the first quarter of 2022 compared to $4.6 million for the first quarter of 2021.

Telix Pharmaceuticals Announces Licence Agreement with Lilly for Olaratumab

Retrieved on: 
Sunday, April 10, 2022

MELBOURNE, Australia and INDIANAPOLIS, April 10, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, "Telix", the "Company") today announces that it has entered into a licence agreement with Eli Lilly and Company ("Lilly") under which Telix is granted exclusive worldwide rights to develop and commercialise radiolabelled forms of Lilly's olaratumab antibody for the diagnosis and treatment of human cancers.

Key Points: 
  • MELBOURNE, Australia and INDIANAPOLIS, April 10, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, "Telix", the "Company") today announces that it has entered into a licence agreement with Eli Lilly and Company ("Lilly") under which Telix is granted exclusive worldwide rights to develop and commercialise radiolabelled forms of Lilly's olaratumab antibody for the diagnosis and treatment of human cancers.
  • The exclusive worldwide licence will allow Telix to repurpose olaratumab as a targeting agent for radiopharmaceutical imaging and therapy of cancer.
  • The agreement also includes an option for Lilly to be granted an exclusive licence to a radiolabelled companion diagnostic which would be developed by Telix.
  • Telix retains termination rights typical to licence agreements of this nature to enable the Company to exit the agreement based on a development or commercial basis.

China Anlotinib Hydrochloride Market Research Report 2021: A Novel Small Molecule Multi-target Tyrosine Kinase Inhibitor that Effectively Inhibits Kinases Like VEGFR, PDGFR, FGFR, and c-Kit - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 7, 2021

The "Research Report on China's Anlotinib Hydrochloride Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Research Report on China's Anlotinib Hydrochloride Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • Anlotinib hydrochloride is a novel small molecule multi-target tyrosine kinase inhibitor that effectively inhibits kinases like VEGFR, PDGFR, FGFR, and c-Kit with anti-tumor angiogenesis and tumor growth inhibition effects.
  • Anlotinib hydrochloride was approved for marketing under the trade name FuKeWei by the NMPA on May 9, 2018, for the third-line treatment of patients with advanced non-small cell lung cancer (NSCLC).
  • The fast time to market anlotinib hydrochloride was made possible by the Chinese government's support for accelerated evaluation and approval of innovative drugs.

Ayvakit Patent, Sales & Clinical Trials Market Insight Report 2021-2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 3, 2021

The "Ayvakit Patent, Sales & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ayvakit Patent, Sales & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.
  • Keeping in mind the sales in previous years and ongoing clinical trials, the report analyzes that the global sales will reach US$ 1 Billion by 2028.
  • The rapid approval of drugs from this class will have a negative impact on the growth of Ayvakit market.
  • Ayvakit Patent, Sales & Clinical Trials Insight 2028 Report Analysis & Data Highlights:

Global PDGFR Inhibitors Market (2021 to 2026) - Featuring AstraZeneca, Bayer and Eli Lilly Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, October 22, 2021

Avapritinib sold under brand name Ayvakit is the first approved PDGFR inhibitor available in market.

Key Points: 
  • Avapritinib sold under brand name Ayvakit is the first approved PDGFR inhibitor available in market.
  • The drug was developed by Blueprint Medicines and is mainly indicated for the treatment of gastrointestinal tumors (GIST) and mastocytosis.
  • Although the market is poised to growth in coming years but several factors limits their growth in market.
  • This will increase the demand of targeted therapies, thus driving the growth of PDGFR inhibitor market.

Benign Prostatic Hyperplasia Pipeline Landscape Report 2021: Therapeutics Assessment by Product Type, Stage, Route of Administration, and Molecule Type - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 28, 2021

This Benign Prostatic Hyperplasia - Pipeline Insight, 2021 provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Benign Prostatic Hyperplasia pipeline landscape.

Key Points: 
  • This Benign Prostatic Hyperplasia - Pipeline Insight, 2021 provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Benign Prostatic Hyperplasia pipeline landscape.
  • It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Benign Prostatic Hyperplasia R&D.
  • Benign Prostatic Hyperplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.